Platelets and cancer: Implications for antiangiogenic therapy
Platelets and cancer: Implications for antiangiogenic therapy
复制标题
DOI：
10.1055/s-2002-20563
复制
发表时间：
2002-02-01
影响因子：
5.7
通讯作者：
Nakada, MT
中科院分区：
文献类型：
--
作者：
Trikha, M;Nakada, MT
血栓栓塞是癌症患者最常见的死亡原因之一。癌症患者最常见的血栓性并发症是弥散性血管内凝血、血栓性血小板减少性紫癜和血小板增多症。显然，这些并发症是由于肿瘤细胞与止血系统的几乎所有组分（包括血小板）相互作用而产生的。血小板通过促进转移级联反应、保护肿瘤细胞免受免疫监视、调节肿瘤细胞侵袭和血管生成来参与肿瘤进展。血小板含有血管生成和促有丝分裂因子的最大储存之一，并且肿瘤脉管系统是渗漏的，这允许血小板与肿瘤接触并将多种血管生成因子（包括血管内皮生长因子（VEGF）和凝血酶）存款至肿瘤细胞，这反过来有助于肿瘤进展。本文综述了血小板在肿瘤生长、血管生成和转移中的作用。
Thromboembolism is one of the most common causes of death in cancer patients. Among the most frequent thrombotic complications in patients with cancer are disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and thrombocytosis. Clearly, these complications arise as tumor cells interact with almost all components of the hemostatic system including platelets. Platelets participate in tumor progression by contributing to the metastatic cascade, protecting tumor cells from immune surveillance, regulating tumor cell invasion, and angiogenesis. Platelets contain one of the largest stores of angiogenic and mitogenic factors and the tumor vasculature is leaky, which allows platelets to come in contact with the tumor and deposit multiple angiogenic factors including vascular endothelial growth factor (VEGF) and thrombin to tumor cells, which in turn contributes to tumor progression. This article reviews the recent literature on how platelets contribute to tumor growth, angiogenesis, and metastasis.